Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Corcept Therapeutics (CORT) over the last 12 years, with Q3 2025 value amounting to $34.4 million.

  • Corcept Therapeutics' Accounts Payables rose 8535.3% to $34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.4 million, marking a year-over-year increase of 8535.3%. This contributed to the annual value of $15.4 million for FY2024, which is 1161.19% down from last year.
  • As of Q3 2025, Corcept Therapeutics' Accounts Payables stood at $34.4 million, which was up 8535.3% from $23.5 million recorded in Q2 2025.
  • Over the past 5 years, Corcept Therapeutics' Accounts Payables peaked at $34.4 million during Q3 2025, and registered a low of $6.6 million during Q3 2021.
  • Over the past 5 years, Corcept Therapeutics' median Accounts Payables value was $12.0 million (recorded in 2022), while the average stood at $14.3 million.
  • In the last 5 years, Corcept Therapeutics' Accounts Payables tumbled by 3454.61% in 2021 and then soared by 14428.28% in 2024.
  • Corcept Therapeutics' Accounts Payables (Quarter) stood at $6.9 million in 2021, then soared by 73.36% to $12.0 million in 2022, then surged by 45.26% to $17.4 million in 2023, then fell by 11.61% to $15.4 million in 2024, then surged by 124.02% to $34.4 million in 2025.
  • Its Accounts Payables stands at $34.4 million for Q3 2025, versus $23.5 million for Q2 2025 and $27.9 million for Q1 2025.